PMID- 18394710 OWN - NLM STAT- MEDLINE DCOM- 20080916 LR - 20220321 IS - 0163-7258 (Print) IS - 0163-7258 (Linking) VI - 118 IP - 1 DP - 2008 Apr TI - Ethanol-BDNF interactions: still more questions than answers. PG - 36-57 LID - 10.1016/j.pharmthera.2008.01.003 [doi] AB - Brain-derived neurotrophic factor (BDNF) has emerged as a regulator of development, plasticity and, recently, addiction. Decreased neurotrophic activity may be involved in ethanol-induced neurodegeneration in the adult brain and in the etiology of alcohol-related neurodevelopmental disorders. This can occur through decreased expression of BDNF or through inability of the receptor to transduce signals in the presence of ethanol. In contrast, recent studies implicate region-specific up-regulation of BDNF and associated signaling pathways in anxiety, addiction and homeostasis after ethanol exposure. Anxiety and depression are precipitating factors for substance abuse and these disorders also involve region-specific changes in BDNF in both pathogenesis and response to pharmacotherapy. Polymorphisms in the genes coding for BDNF and its receptor TrkB are linked to affective, substance abuse and appetitive disorders and therefore may play a role in the development of alcoholism. This review summarizes historical and pre-clinical data on BDNF and TrkB as it relates to ethanol toxicity and addiction. Many unresolved questions about region-specific changes in BDNF expression and the precise role of BDNF in neuropsychiatric disorders and addiction remain to be elucidated. Resolution of these questions will require significant integration of the literature on addiction and comorbid psychiatric disorders that contribute to the development of alcoholism. FAU - Davis, Margaret I AU - Davis MI AD - Section on Synaptic Pharmacology, Laboratory for Integrative Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA. midavis@mail.nih.gov LA - eng GR - Z99 AA999999/ImNIH/Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Intramural PT - Review DEP - 20080202 PL - England TA - Pharmacol Ther JT - Pharmacology & therapeutics JID - 7905840 RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Central Nervous System Depressants) RN - 3K9958V90M (Ethanol) RN - EC 2.7.10.1 (Receptor, trkB) SB - IM MH - Alcoholism/drug therapy/physiopathology MH - Animals MH - Brain-Derived Neurotrophic Factor/*drug effects/metabolism MH - Central Nervous System Depressants/*adverse effects MH - Disease Models, Animal MH - Drug Delivery Systems MH - Ethanol/*adverse effects MH - Female MH - Fetal Alcohol Spectrum Disorders/physiopathology MH - Humans MH - Nerve Degeneration/chemically induced/physiopathology MH - Pregnancy MH - Receptor, trkB/drug effects/metabolism MH - Signal Transduction/drug effects PMC - PMC2553254 MID - NIHMS51309 EDAT- 2008/04/09 09:00 MHDA- 2008/09/17 09:00 PMCR- 2009/04/01 CRDT- 2008/04/09 09:00 PHST- 2008/01/04 00:00 [received] PHST- 2008/01/08 00:00 [accepted] PHST- 2008/04/09 09:00 [pubmed] PHST- 2008/09/17 09:00 [medline] PHST- 2008/04/09 09:00 [entrez] PHST- 2009/04/01 00:00 [pmc-release] AID - S0163-7258(08)00015-6 [pii] AID - 10.1016/j.pharmthera.2008.01.003 [doi] PST - ppublish SO - Pharmacol Ther. 2008 Apr;118(1):36-57. doi: 10.1016/j.pharmthera.2008.01.003. Epub 2008 Feb 2.